Related Experiment Videos
Liver function abnormality following treatment with antithymocyte globulin for aplastic anaemia
S B Killick1, J C Marsh, J C Booth
1Department of Cellular and Molecular Sciences, St George's Hospital, London, UK.
Bone Marrow Transplantation
|February 1, 1997
Summary
Antithymocyte globulin (ATG) treatment for aplastic anemia can cause temporary elevations in alanine transaminase (ALT) levels. Most cases resolve within 30 days, but some may persist, warranting further investigation into ATG
Area of Science:
- Hepatology
- Hematology
- Clinical Pharmacology
Background:
- Aplastic anemia is a rare but serious bone marrow failure disorder.
- Antithymocyte globulin (ATG) is a common immunosuppressive therapy for aplastic anemia.
- Elevated liver enzymes can indicate hepatotoxicity, necessitating careful monitoring during treatment.
Purpose of the Study:
- To investigate the incidence and pattern of alanine transaminase (ALT) elevations in aplastic anemia patients treated with ATG.
- To determine the potential causes and clinical significance of ATG-associated ALT elevations.
Main Methods:
- Retrospective analysis of 18 patient episodes of aplastic anemia treated with ATG over 12 months.
- Monitoring of serum ALT levels and assessment for viral infections and other drug toxicities.
Main Results:
- Fifteen out of 18 patient episodes (83%) showed transient elevations in ALT levels.
- ALT levels ranged from 1.2 to 18.5 times the upper limit of normal.
- While most elevations resolved within 30 days, two cases persisted for 6 months, and two persisted until death.
Conclusions:
- Transient ALT elevations are a common finding in aplastic anemia patients receiving ATG.
- The elevations may be due to non-specific binding of ATG to hepatocytes or an unidentified infectious agent.
- Further research is needed to elucidate the exact mechanism and clinical implications.